Initial response of renal cell carcinoma to vemurafenib in a patient treated for metastatic melanoma

Authors

  • Gregory W. Hosier Dalhousie University
  • Matthew T. Roberts University of Ottawa

DOI:

https://doi.org/10.5489/cuaj.3652

Abstract

Vemurafenib is a selective inhibitor of overactive BRAF oncogene with a substitution of lysine for glutamic acid at residue 600 (BRAFV600E), a mutation expressed in approximately 50% of all melanomas. We report a case of a patient with metastatic melanoma treated with vemurafenib, who subsequently presented with a biopsy-proven conventional renal cell carcinoma (RCC). We observed an initial complete regression of the mass while on vemurafenib. This was unexpected, given that vemurafenib is a specific inhibitor of BRAFV600E and most RCCs do not harbour this mutation.

Downloads

Download data is not yet available.

Author Biography

Gregory W. Hosier, Dalhousie University

Medical student

Downloads

Published

2016-09-13

How to Cite

Hosier, G. W., & Roberts, M. T. (2016). Initial response of renal cell carcinoma to vemurafenib in a patient treated for metastatic melanoma. Canadian Urological Association Journal, 10(9-10), E306–8. https://doi.org/10.5489/cuaj.3652

Issue

Section

Residents' Room